NUCLEIX LTD

Their core work

Nucleix is an Israeli biotech SME that develops blood-based cancer diagnostics using epigenetic biomarkers — specifically, the analysis of DNA methylation patterns in circulating cell-free DNA extracted from blood samples. Their core technology is a liquid biopsy platform that can detect cancer-specific epigenetic signatures without invasive tissue biopsies. They progressed from a broad pan-cancer detection concept to a commercially focused lung cancer diagnostic product called Lung EpiCheck, suggesting a deliberate market narrowing toward one of the highest-burden cancers. Based in Rehovot — Israel's main biotech cluster near the Weizmann Institute — they operate as an independent R&D company with EU co-funding for clinical and commercial validation.

What they specialise in

How they've shifted over time

Nucleix began with an ambitious multi-cancer detection concept — EPICHECK (2015) proposed screening for various cancer types from a single blood sample using epigenetic markers. By 2018, they had narrowed sharply: Lung EpiCheck targets lung cancer specifically, with nearly 50× more EU funding, suggesting that clinical validation or commercial feedback pointed to lung cancer as the strongest near-term opportunity. This is a textbook SME Instrument trajectory — Phase 1 tests the broad concept, Phase 2 doubles down on the most viable application. The direction is toward clinical-grade, market-ready diagnostics rather than platform-level research.

Nucleix is moving toward a commercially deployable lung cancer diagnostic product, having used EU SME funding as a clinical validation pathway — any future collaboration is likely to be about clinical trials, regulatory approval, or market entry rather than basic research.

How they like to work

Nucleix has exclusively led projects as sole coordinator — both grants came through the SME Instrument, a scheme designed for individual companies rather than consortia, which explains why no consortium partners appear in their record. This means they are highly self-sufficient technically but may lack experience integrating into large multi-partner research consortia. Anyone approaching them should expect to deal directly with the company, not through a network of academic or industrial co-leads.

No EU consortium partners are recorded across either project, consistent with the solo-company nature of the SME Instrument scheme they used. As an Israeli organization participating under a bilateral association agreement, their European network visibility is limited even though they have accessed substantial EU funding.

What sets them apart

Nucleix occupies a specific and defensible niche: epigenetic liquid biopsy for cancer detection, developed by an Israeli SME with validated access to EU funding. Israel's biotech ecosystem — particularly the Rehovot cluster — is known for translational diagnostics companies, and Nucleix's successful scale from a EUR 50K feasibility grant to EUR 2.46M implementation funding suggests they have clinical data backing their approach. For consortia needing a diagnostics SME with a non-invasive cancer detection angle, they bring both proprietary technology and a track record of EU project management as coordinator.

Highlights from their portfolio

• Lung EpiCheck
  The largest project by far at EUR 2.46M, representing a full SME Instrument Phase 2 implementation — the highest competitive EU grant available to individual SMEs at the time, awarded for a commercially-focused lung cancer diagnostic product.
• EPICHECK
  The Phase 1 feasibility grant (EUR 50K) that seeded the entire programme, proposing a pan-cancer epigenetic blood test concept that later matured into the lung-cancer-specific product.